Curia Appoints Philip Macnabb as Chief Executive Officer
ALBANY, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced that Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff.
“On behalf of the Board of Directors, we thank John Ratliff for the tremendous progress that Curia made during his tenure,” said Curia board members Sean Cunningham, managing director, GTCR and William McMullan, managing director, Carlyle. “We are delighted to welcome Phil, a seasoned executive who has an impressive track record of focusing companies on their core value proposition, enhancing the customer experience and building organizations with real and sustaining value. Curia is well positioned in the growing CDMO market, and we are excited about its outlook under Phil’s leadership.”
Mr. Macnabb commented: “Curia is a unique company with deep scientific expertise across its end-to-end offering. We have incredible people in the global Curia community, who are highly motivated by our noble purpose of improving patients lives. Going forward, we will focus on creating sustainable value for customers and employees.”
Macnabb joins Curia having spent years in leadership roles at various companies in the healthcare industry. Prior to that, Macnabb held senior positions in technology, distribution, and consumer products segments. He received an MBA from the University of Chicago and a BS in Business Administration from Purdue University.
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
+1 518 512 2111
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1ee2752-5afe-44c8-ab11-33a29f2137f0To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Oxurion Publishes 2022 Annual Report31.3.2023 20:42:16 CEST | Press release
Regulated Information Leuven, BELGIUM,Boston, MA, US–March 31, 2023– 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2022. The annual report for the year ending December 31, 2022 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeut
Iceland Seafood International hf completes auction of bills31.3.2023 20:33:29 CEST | Press release
Iceland Seafood International hf. has concluded an offering of 3-month bills in the new series ICESEA 23 0705. Total offers for bills in the auction amounted to ISK 1.500 million which were all accepted, at a simple rate of 11.00%. The bills are scheduled to be admitted to trading on Nasdaq Iceland in the coming weeks.
Nokia Corporation: Repurchase of own shares on 31.03.202331.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 31 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 31.03.2023 Espoo, Finland – On 31 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL221,1864.49CEUX21,0654.50AQEU12,3894.49TQEX7,3604.50Total262,0004.49 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 a
Fly Play hf.: Amendments to share option plan31.3.2023 20:00:00 CEST | Press release
Amendments to share option plan As detailed in the Company Description in relation to the listing of shares in Fly Play hf. on Nasdaq First North Iceland, dated June 2021, the Company had, in accordance with the remuneration then in force, implemented a share-based incentive program in the form of option rights whereby the Company granted several members of the management team and other key employees options to purchase shares in the Company as part of their remuneration. Having regard for the purposes of the share-based incentive program referred to above, the Board of Directors has decided to extend the exercise period in relation to share options to purchase a total of 16.666.669 shares in the Company, at a purchase price of ISK 8 per share. For a period of 12 months, these options are therefore exercisable until April 2024, at which point the options expire. The options may be exercised at any time during the exercise period.
SBM Offshore completes US$1.63 billion financing of Almirante Tamandaré31.3.2023 19:25:15 CEST | Press release
March 31, 2023 SBM Offshore is pleased to announce it has signed the project financing of FPSO Almirante Tamandaré for a total of US$1.63 billion. The project financing is provided by a consortium of 13 international banks with insurance cover from 4 international Export Credit Agencies (ECA). The financing is composed of five separate facilities with a ca. 6.3% weighted average cost of debt and a 14-year post-completion maturity for both the ECA covered facilities and the uncovered facility. The FPSO’s design incorporates SBM Offshore’s industry leading Fast4Ward® new build, multi-purpose hull. It will be the largest oil producing unit in Brazil with a processing capacity of 225,000 barrels of oil and 12 million m3 of gas per day. The FPSO will have an estimated greenhouse gas (GHG) emission intensity below 10 kgCO2e/boe1 and will benefit from emission reduction technologies such as the closed flare technology which increases gas utilization, preventing it from being burnt into the at